Nezglyal remains promising therapy despite EMA’s market authorisation refusal: GlobalData EP News Bureau Feb 29, 2024 Nezglyal is a novel orally bioavailable and selective peroxisome proliferator-activated receptor (PPAR) gamma agonist that is…
